文献速递头颈神经CTMRPET

颈动脉影像报告和数据系统(NI-RADS)诊断头颈部鳞状细胞癌复发的效能:系统评价与Meta分析

Performance of Neck Imaging Reporting and Data System (NI-RADS) for Diagnosis of Recurrence of Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-analysis.
PubMed 文献 · AJNR Am J Neuroradiol · 2023-09-14

该系统评价纳入7项研究共694例患者(1233个病灶),评估NI-RADS各分类的复发检出率并比较NI-RADS 2与3界值的诊断准确性。原发灶NI-RADS 3、2、1类复发率分别为74.4%、29.0%、4.2%,颈部淋巴结分别为73.3%、14.3%、3.5%。以NI-RADS 3为界值的汇总受试者工作特征曲线下面积(原发灶0.887、淋巴结0.983)高于以NI-RADS 2为界值(分别为0.869、0.919),NI-RADS 3对复发检测具有高诊断效能,但数据异质性大,结论需谨慎解读。

要点

  • 原发灶NI-RADS 3类复发率74.4%,NI-RADS 2类29.0%,NI-RADS 1类4.2%。
  • 颈部淋巴结NI-RADS 3类复发率73.3%,NI-RADS 2类14.3%,NI-RADS 1类3.5%。
  • 以NI-RADS 3为界值的AUC原发灶0.887、淋巴结0.983,均高于NI-RADS 2界值。

核心结论

  • Meta分析显示NI-RADS各分类的原发灶和颈部淋巴结复发率估计值,NI-RADS 3对复发检测具有高诊断效能;鉴于研究数据异质性,结论应谨慎解读。

研究设计与样本

  • 系统评价与Meta分析,检索MEDLINE、Scopus和EMBASE数据库,纳入7项研究共694例患者(1233个病灶)。

诊断标准与关键数值

  • 原发灶复发率:NI-RADS 3类74.4%,NI-RADS 2类29.0%,NI-RADS 1类4.2%。
  • 颈部淋巴结复发率:NI-RADS 3类73.3%,NI-RADS 2类14.3%,NI-RADS 1类3.5%。
  • 以NI-RADS 3为界值的汇总受试者工作特征曲线下面积:原发灶0.887,颈部淋巴结0.983。
  • 以NI-RADS 2为界值的汇总受试者工作特征曲线下面积:原发灶0.869,颈部淋巴结0.919。

临床应用与阅片要点

  • 原文结论为NI-RADS 3对复发检测具有高诊断效能,但鉴于数据异质性结论应谨慎解读。

局限性

  • 鉴于研究数据的异质性,结论应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: The Neck Imaging Reporting and Data System (NI-RADS) is a reporting template used in head and neck cancer posttreatment follow-up imaging.

PURPOSE: Our aim was to evaluate the pooled detection rates of the recurrence of head and neck squamous cell carcinoma based on each NI-RADS category and to compare the diagnostic accuracy between NI-RADS 2 and 3 cutoffs.

DATA SOURCES: The MEDLINE, Scopus, and EMBASE databases were searched.

STUDY SELECTION: This systematic review identified 7 studies with a total of 694 patients (1233 lesions) that were eligible for the meta-analysis.

DATA ANALYSIS: The meta-analysis of pooled recurrence detection rate estimates for each NI-RADS category and the diagnostic accuracy of recurrence with NI-RADS 3 or 2 as the cutoff was performed.

DATA SYNTHESIS: The estimated recurrence rates in each category for primary lesions were 74.4% for NI-RADS 3, 29.0% for NI-RADS 2, and 4.2% for NI-RADS 1. The estimated recurrence rates in each category for cervical lymph nodes were 73.3% for NI-RADS 3, 14.3% for NI-RADS 2, and 3.5% for NI-RADS 1. The area under the curve of the summary receiver operating characteristic for recurrence detection with NI-RADS 3 as the cutoff was 0.887 and 0.983, respectively, higher than 0.869 and 0.919 for the primary sites and cervical lymph nodes, respectively, with NI-RADS 2 as the cutoff.

LIMITATIONS: Given the heterogeneity of the data of the studies, the conclusions should be interpreted with caution.

CONCLUSIONS: This meta-analysis revealed estimated recurrence rates for each NI-RADS category for primary lesions and cervical lymph nodes and showed that NI-RADS 3 has a high diagnostic performance for detecting recurrence.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Baba A, Kurokawa R, Kurokawa M, et al. Performance of Neck Imaging Reporting and Data System (NI-RADS) for Diagnosis of Recurrence of Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-analysis. AJNR Am J Neuroradiol. 2023. PMID: 37709352. doi:10.3174/ajnr.A7992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。